Go to Prelude
Go to interview with Lisa Carey, MD
Go to interview with Generosa Grana, MD
Go to interview with Jenny C Chang, MD
Go to interview with Ms D
Go to interview with Ms K
 
 
To listen to individual tracks now, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
     
  Prelude

  
  Click here to download the prelude  
Track 1 Prelude: Patient perspectives on the diagnosis and treatment of breast cancer
     
Carey, MD Lisa Carey, MD
Associate Professor
Hematology and Oncology Clinical
Research Program
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Challenges of managing patients with newly diagnosed metastatic disease
Track 3 Factors influencing the treatment approach to newly diagnosed metastatic disease
Track 4 Selection of first-line hormonal therapy in the metastatic setting
Track 5 Side effects of fulvestrant versus the aromatase inhibitors
Track 6 Future directions in clinical research with hormonal therapy in the adjuvant setting
Track 7 Efficacy and tolerability of bevacizumab in combination with chemotherapy
Track 8 Nab paclitaxel versus weekly paclitaxel as first-line therapy for metastatic disease
Track 9 Management of HER2-positive metastatic disease
Track 10 Potential role and benefits of lapatinib in the management of HER2-positive breast cancer
Track 11 Side effects of lapatinib versus trastuzumab audio
Track 12 Clinical use of trastuzumab in the adjuvant setting audio
Track 13 Risk of cardiac toxicity with adjuvant trastuzumab audio
Track 14 Reversibility of cardiac toxicity associated with trastuzumab audio
Track 15 Development, validation and clinical use of the Oncotype DX™ assay audio
     
Grana, MD Generosa Grana, MD
Associate Professor of Medicine
UMDNJ/Robert Wood Johnson
School of Medicine
Director, Breast Cancer Program
Cooper Hospital
Camden, New Jersey

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Impact of breast cancer recurrence on oncologists and nurses
Track 3 Factors influencing management approach in the metastatic setting
Track 4 Mechanisms of action of fulvestrant, aromatase inhibitors and tamoxifen
Track 5 Sequential single-agent versus combination chemotherapy in the metastatic setting
Track 6 Potential benefits of nanoparticle albumin-bound (nab) paclitaxel
Track 7 Management of neurotoxicity associated with the taxanes
Track 8 Efficacy, side effects and reimbursement of bevacizumab
Track 9 Utility of Oncotype DX in treatment decision-making
Track 10 Optimal approach to hormonal therapy in the adjuvant setting
Track 11 Efficacy and tolerability of the aromatase inhibitors versus tamoxifen
Track 12 Selection of an adjuvant chemotherapeutic regimen
Track 13 Management of HER2-positive disease in the adjuvant setting
Track 14 Incidence and impact of cardiac toxicity associated with adjuvant trastuzumab
Track 15 FISH versus IHC testing to assess HER2 positivity
Track 16 Efficacy and tolerability of lapatinib
     
Jenny C Chang, MD
Associate Professor
Breast Center at Baylor College of Medicine
Houston, Texas
 
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Factors influencing treatment approach in the adjuvant setting
Track 3 Lack of quality control with ER, PR and HER2 testing
Track 4 Selection of adjuvant hormonal therapy
Track 5 Mechanisms of action of different hormonal therapies
Track 6 Duration of adjuvant hormonal therapy
Track 7 Potential role of aromatase inhibitors for the prevention of breast cancer
Track 8 Clinical use of the Oncotype DX assay
Track 9 Adjuvant trastuzumab in patients with low-risk HER2-positive disease
Track 10 Synergy between trastuzumab and different chemotherapeutic agents
Track 11 Efficacy and tolerability of nab paclitaxel versus the other taxanes
Track 12 Efficacy and tolerability of bevacizumab
Track 13 Selection of hormonal therapy in the metastatic setting
Track 14 Clinical use of a loading dose with fulvestrant
     
  Ms D

 
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Coping with a diagnosis of breast cancer
Track 3 Side effects and tolerability of adjuvant chemotherapy
Track 4 Tolerability of adjuvant anastrozole
Track 5 Rationale for the selection of adjuvant anastrozole over tamoxifen
Track 6 Impact of cancer diagnosis and treatment on personal outlook and family relationships
     
  Ms K

 
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Side effects of adjuvant chemotherapy
Track 3 Personal perspective on completing treatment with adjuvant trastuzumab
Track 4 Change in personal outlook and life perspective after breast cancer